• Glenn Muir, Executive Vice President and Chief Financial Officer, will present at:
  - The Leerink Swann 2012 Global Healthcare Conference in New York City, New York on Wednesday, February 15, 2012 at 11:30 a.m. (Eastern).
  - The 2012 RBC Capital Markets' Global Healthcare Conference in New York City, New York on Tuesday, February 28, 2012 at 9:30 a.m. (Eastern).

• Rob Cascella, President and Chief Executive Officer, will present at:
  - The Citi 2012 Global Health Care Conference in New York City, New York on Monday, February 27, 2012 at 9:30 a.m. (Eastern).
  - The Barclays Capital Global Healthcare Conference in Miami, Florida on Tuesday, March 13, 2012 at 8:00 a.m. (Eastern).

Interested parties are invited to listen to the live audio webcasts of the investor presentations on the investor section of Hologic's website at www.hologic.com/investors-overview. Archives of the presentations will be available for replay following the conferences.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

BEDFORD, Mass., Dec. 15, 2011 / -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test. The Company's HPV HR test utilizes Hologic's proprietary Invader technology to detect 14 high risk types of HPV that are associated with cervical cancer and precancerous lesions.

The Company's Cervista HTA system automates the DNA extraction and detection steps of the Hologic Cervista HPV HR test allowing users to walk away after loading the instrument and return the next morning to review the test results.

"Our new Cervista high throughput automation system represents a significant addition to our molecular diagnostics product portfolio," said Rob Cascella, President and Chief Executive Officer of Hologic. "The Cervista HTA system automates our Cervista HPV HR test, providing higher throughput, improved chain of custody and accurate results. We are extremely pleased to get this product approved as it materially changes the competitive landscape for Hologic."

"With over 200 U.S. laboratories currently running our Cervista HPV HR test, we have had tremendous success with the early adoption of our manual HPV test," said Rohan Hastie, Vice President and General Manager, Hologic Molecular Diagnostics. "We believe that our success is driven in large part by physician and laboratory confidence in the performance and comprehensive design of the Cervista HPV assays. Having HTA approved quite simply makes us even more competitive."

Approval of the Cervista HTA system provides Hologic, a world leader in cervical cancer screening, the most complete cervical cancer screening solution available on the market today.

About the ThinPrep Pap Test and Cervista HPV HR and Cervista HPV 16/18 Tests
Research on human papillomavirus has made impressive progress in recent years. Better diagnosis and therapies have helped to significantly reduce the number of new cancer cases, advanced-stage tumors, and ultimately deaths from cervical cancer in particular, which is predominantly caused by HPV. Next to breast cancer, cervical cancer remains the second most frequent cancer affecting women worldwide.

Hologic has been dedicated to the prevention of cervical cancer through screening since the introduction of its ThinPrep Pap Test in 1996. The ThinPrep Pap Test today is the most widely-used liquid based cytology platform in the United States and many other countries of the world. In 2003, Hologic was the first to introduce a computer-guided imaging system for cervical cancer screening with the approval of its ThinPrep Imaging System which has since become the standard of care for the majority of ThinPrep customers. With the approval of the Company's Cervista HTA system, Hologic offers a complete cervical cancer screening solution that is scalable for all laboratory customers.

The Cervista HTA system has the ability to process multiple batch sizes of samples providing high-to-mid-volume laboratories the opportunity to utilize Hologic's automation and use the reagents efficiently.

Hologic's unique combination of cytology and molecular products, including the ThinPrep Pap, Cervista HPV HR and Cervista HPV 16/18 tests, provides a full range of cervical cancer screening technologies for improving women's health.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, Cervista, Invader and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the ThinPrep Pap Test, Cervista HPV HR test, Cervista HTA system and ThinPrep Imaging System. There can be no assurance the tests or systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner as the actual effect of the use of the tests and systems can only be determined on a case-by-case basis depending on the particular circumstances and installation in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

BEDFORD, Mass., November 27, 2011 /PRNewswire/ - Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the commercial release of its C-View synthesized 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a 3D mammography( tomosynthesis breast cancer screening) exam. C-View software is approved for sale throughout the European Economic Area and in other countries recognizing the CE Mark.

For users of Hologic's 2D plus 3D tomosynthesis breast cancer screening system, C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures.

Dr. Stephen Rose, a board certified radiologist with Houston Breast Imaging, one of the first U.S. radiologists to adopt breast tomosynthesis, stated "Hologic's synthesized 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic's combo-mode (2D plus 3D) imaging."

Hologic is featuring the new algorithm along with the Company's Selenia Dimensions breast tomosynthesis system at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the largest radiology show in the world, taking place at McCormick Place in Chicago November 26 through December 2.

Hologic is the global market leader in 3D mammography (breast tomosynthesis) with its Selenia Dimensions platform. In Hologic's clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, C-View, Dimensions and Selenia are trademarks and/or registered trademarks of Hologic, Inc, and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance that the C-View synthesized 2D image reconstruction algorithm when used with a Selenia Dimensions breast tomosynthesis system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

BEDFORD, Mass., Nov. 21, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will feature some of its newest women's health products at the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago, November 26 through December 2.

Products highlighted this year include:

3D Mammography (Breast Tomosynthesis). The Hologic Selenia Dimensions 2D + 3D system systems provides radiologists measurable improvements in specificity and sensitivity over conventional digital mammography and increases radiologists confidence in ruling out breast cancer without a recall. For the first time ever, Selenia Dimensions breast tomosynthesis allows radiologists to offer their patients a conventional 2D digital mammogram and a 3D tomosynthesis exam in one compression, in just seconds at a dose below the U.S. mammography screening guidelines.

Hologic is offering five 90-minute programs combining lectures and hands-on experience for radiologists and other medical professionals interested in learning more about breast tomosynthesis technology. Six scientific papers that discuss the use of Hologic tomosynthesis in clinical breast cancer screening practices will be presented at RSNA.

A synthesized 2D image reconstruction algorithm commercially available outside the U.S. will be presented at the meeting. The algorithm is designed to create a 2D image from the tomosynthesis projection data, thereby eliminating the need for a 2D exposure, while maintaining superior performance to a conventional 2D-only FFDM exam.

Breast Biopsy Devices. Innovation coupled with a focus on quality and customer service has made Hologic the leading U.S. producer of vacuum-assisted breast biopsy devices. Shown for the first time at RSNA as a commercially-available system in the U.S. and in countries recognizing the CE mark, the Hologic Affirm guidance system gives facilities the opportunity to offer leading-edge technology in minimally invasive breast biopsy. The system's pre-programmed settings for Hologic Eviva and ATEC biopsy devices are designed to offer radiologists quick and efficient set-up for reduced procedure times.

Specimen Radiography. Frequently, breast specimen imaging is performed directly on a facility's mammography system taking time away from using the system for normal screening and diagnostic exams. In addition, if the clinician leaves the procedure to confirm the specimen image, the patient often needs to stay under anesthesia and/or in compression during this time.

The recently cleared Hologic Trident mobile specimen radiolography system uses proprietary direct digital detector technology designed to produce high-quality images for rapid verification of tissue specimens such as breast biopsy samples.

Magnetic Resonance Imaging Products. Also shown for the first time at RSNA is the recently cleared Hologic Sentinelle Endo Coil for pelvic imaging, including staging for prostate cancer. A 90-minute program that combines lectures and hands-on experience reading prostate MRI cases with visualization and analysis software is available for radiologists interested in the new technology.

"RSNA provides an opportunity for Hologic to showcase our new and innovative products, such as 3D breast tomosynthesis for breast cancer screening and diagnosis," stated Rob Cascella, President and CEO of Hologic. "This has been an exciting year for Hologic as we continue our focus on improving technology for the diagnosis and treatment of breast cancer. In addition to 3D mammography, we introduced a number of other new imaging technologies and will have them all on display at the Annual Meeting of the Radiological Society of North America, the largest radiology show in the world."

Other Hologic products expected to generate considerable interest include:

• Breast density is a clinically significant predictor of breast cancer risk, almost as significant as a woman's age. Hologic Quantra technology estimates volumes in the breast and calculates the volumetric fraction of fibroglandular tissue.
  
• Hologic Advanced Body Composition software for its Discovery platform can help patients and physicians establish goals for weight loss, exercise and diet regimes. The software targets a major problem impacting 59 million American adults - obesity.
  
• A work-in-progress this year is the Hologic Fluoroscan InSight-FD mini C-arm with an innovative high-resolution flat detector that rivals standard x-ray images in a mini fluoroscopy system.

For a more extensive listing of products that Hologic will be featuring at RSNA 2011, click here.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, Advanced Body Composition, Affirm, ATEC, Celero, Dimensions, Discovery, Eviva, Fluoroscan, Quantra, Selenia, Sentinelle and Trident are trademarks and/or registered trademarks of Hologic, Inc, and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

BEDFORD, Mass., November 7, 2011. Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase a comprehensive suite of gynecologic surgical products at AAGL 40th Annual Global Congress of Minimally Invasive Gynecology, November 6-10, 2011, at the Westin-Diplomat Hotel in Hollywood, Florida.

Hologic's GYN surgical products provide innovative minimally invasive alternatives for physicians to make available to women who often do not realize they have options to traditional surgeries such as tubal ligation and hysterectomy.

"Hologic and our OB/GYN customers strive to educate women about options to traditional surgery that do not require incisions, lengthy hospital stays or the unnecessary removal of major organs," said Shacey Petrovic, Vice President of Marketing for GYN Surgical Products at Hologic. "Demand for minimally invasive procedures continues to climb as an increasing number of gynecologists perform procedures in-office, resulting in shorter patient recovery times and significant cost benefits."

At this year's AAGL Congress, Hologic is showcasing three new products and a new partnership agreement.

The Hologic Aquilex fluid control system is designed for high aspiration outflow procedures such as the Hologic MyoSure hysteroscopic tissue removal system, making it the highest-performing fluid management system with integrated vacuum capability on the market. The Aquilex system is designed to simplify hysteroscopy through easy set-up and minimized risk of inaccurate deficit readings. Its high inflow rate capability and integrated suction design are intended to rapidly achieve and hold constant distention independent of hysteroscope diameter to improve visualization of the uterine cavity throughout the procedure.

The Company will have on display a new simulation system, GyneSim, a platform for realistic teaching and training of transcervical procedures. The GyneSim is optimized for the MyoSure system and will be used for physician education, resident training and sales training. Hologic representatives will be available at the Congress to offer hands-on, virtual reality training demonstrations.

In October, Hologic received CE marking approval for the next generation of the Adiana permanent contraception (Adiana) system. Adiana is a minimally invasive procedure that requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. It is designed to provide women with an alternative to traditional, surgical means of permanent contraception such as tubal ligation. Featuring a biocompatible radiopaque matrix, CE marking approval allows Hologic to market Adiana permanent contraception with the radiopaque matrix in the 27 countries of the European Union and three of the four member states of the European Free Trade Association.

AAGL 2011 also marks the announcement of Hologic's strategic partnership agreement with KARL STORZ Endoscopy America, Inc. giving Hologic's GYN Surgical division the exclusive distribution rights to a new video platform and hysteroscopic instrumentation to further the adoption of minimally-invasive procedures in the office setting. The new agreement enhances the existing Hologic THS tower-free hysteroscopy system and will enable physicians to perform the NovaSure endometrial ablation, Adiana, and MyoSure procedures in their offices.

"KARL STORZ is a leader in endoscopy and visualization with a reputation for quality products, strong key opinion leader relationships, and a dedication to the development of innovative endoscopic surgical technologies," said Steve Williamson, Senior Vice President and General Manager, GYN Surgical Products at Hologic. "This partnership agreement enables Hologic to continue the delivery of best-in-class physician training and increase the accessibility of in-office procedures for women."

In 2011 Hologic celebrated the 10-year anniversary of the NovaSure system, a simple, one-time, five-minute procedure for heavy menstrual bleeding, or menorrhagia. Heavy periods affect one in five women and often begin when women reach ages in their 30s and 40s. Since 2001, more than 1.5 million women have been treated with the NovaSure procedure to reduce or eliminate menstrual bleeding, without hormones or an invasive hysterectomy.

For more information about Hologic's gynecologic surgical products, presentations and sessions at AAGL, please visit booth 411.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast Magnetic Resonance Imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the NovaSure system, the THS tower-free hysteroscopy system and the Aquiflex system. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of these systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic, Adiana, Aquilex, MyoSure, NovaSure, THS and Total Office Solution are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

BEDFORD, Mass., Oct. 25, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products, announced today that the U.S. Food and Drug Administration (FDA) has cleared two Hologic magnetic resonance imaging (MRI) products: the Sentinelle 2-channel Endo Coil and Sentinelle's 16 channel Breast Coil for several Siemens platforms.

The Sentinelle MRI Endo Coil array for pelvic imaging provides a new solution for imaging and analysis of the pelvic region. The Endo Coil employs Hologic's innovative technology designed to provide high signal-to-noise imaging to help visualize and localize cancers in the pelvic region, and especially prostate cancer. Siemens and Toshiba are completing final release processes to enable product shipments in 2012.

Hologic's new 16 channel Sentinelle Breast Coil builds on the Company's strength in breast MRI interventional and analysis solutions for managing breast cancer. The new Breast Coil array is designed to provide excellent signal-to-noise ratio as well as optimal access for breast biopsies. The 16 channel array is pending validation by Siemens and will initially be available on the Siemens TIM (Total Imaging Matrix) platforms, followed by validation on the Siemens Aera and Skyra MRI platforms.

"We are excited about the possibilities these new products bring healthcare professionals for finding and treating breast and prostate cancer at the earliest stage possible," says Peter Soltani, Ph.D., Senior Vice President and General Manager of Hologic's Breast Health Division. "For the past decade, Hologic has worked diligently to help healthcare professionals diagnose and treat breast cancer at its earliest stages. Our newest 16 channel Sentinelle MRI Breast Coil array is yet another innovative tool added to that arsenal. In addition, we are very pleased with the FDA clearance of our new Sentinelle Endo Coil to address another debilitating disease state: prostate cancer."

About Hologic MRI Solutions

Hologic offers imaging, interventional and analysis solutions for breast MRI. Unlike competitive breast coils, Hologic's Variable Coil Geometry feature allows for the diagnostic coils and biopsy grid positioning to conform to each patient. This innovation can improve image quality, decrease set-up time, increase patient accommodation and improve access to lesions for biopsy. When combined with the Hologic ATEC minimally-invasive breast biopsy device for MRI and Hologic Aegis software for image analysis and interventional planning, the Company provides a unique suite of products.

The Company's MRI Endo Coil array for pelvic imaging provides a new solution for imaging and analysis of the pelvic region including the prostate, cervix, colon and the surrounding tissues in the pelvis. Complementing the Endo Coil array, MRI solutions offer a prostate plug in for analysis of prostate MR images to the Aegis software platform.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Hologic, Aegis, ATEC, Sentinelle, Variable Coil Geometry and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Hologic MRI products. There can be no assurance the systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.